Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 3

1(20.0%)

Early Phase 1

1(20.0%)

5Total

Phase 2(3)

Phase 3(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05153499Phase 3Terminated

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

Role: lead

NCT03110133Phase 2Completed

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff

Role: lead

NCT03497806Phase 2Completed

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Role: lead

NCT03829878Phase 2Withdrawn

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)

Role: lead

NCT03527056Early Phase 1Withdrawn

Pilot Study Using Oral Capsule FMT to Decolonize GI CRE

Role: collaborator

All 5 trials loaded